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Background: Early appearance of antibodies specific for native human type II collagen (anti-CII) characterizes an
early inflammatory and destructive phenotype in adults with rheumatoid arthritis (RA). The objective of this study
was to investigate the occurrence of anti-CII, IgM RF, IgA RF and anti-CCP in serum samples obtained early after
diagnosis, and to relate the occurrence of autoantibodies to outcome after eight years of disease in children with
juvenile idiopathic arthritis (JIA).
Methods: The Nordic JIA database prospectively included JIA patients followed for eight years with data on remission
and joint damage. From this database, serum samples collected from 192 patients, at a median of four months after
disease onset, were analysed for IgG anti-CII, IgM RF, IgA RF and IgG anti-CCP. Joint damage was assessed based on
Juvenile Arthritis Damage Index for Articular damage (JADI-A), a validated clinical instrument for joint damage.
Results: Elevated serum levels of anti-CII occurred in 3.1%, IgM RF in 3.6%, IgA RF in 3.1% and anti-CCP in 2.6% of the
patients. Occurrence of RF and anti-CCP did to some extent overlap, but rarely with anti-CII. The polyarticular and
oligoarticular extended categories were overrepresented in patients with two or more autoantibodies. Anti-CII occurred
in younger children, usually without overlap with the other autoantibodies and was associated with high levels of
C-reactive protein (CRP) early in the disease course. All four autoantibodies were significantly associated with joint
damage, but not with active disease at the eight-year follow up.
Conclusions: Anti-CII, anti-CCP, IgA RF and IgM RF detected early in the disease course predicted joint damage when
assessed after eight years of disease. The role of anti-CII in JIA should be further studied.
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Juvenile idiopathic arthritis (JIA) is a heterogeneous con-
dition with time of onset before the age of 16. The diver-
sity in clinical manifestations differs from that in adult
arthritis, but some findings point to similarities among
children and adults. Reliable biomarkers for prediction of
outcome and choice of treatment in JIA are scarce [1].* Correspondence: lillemor.berntson@telia.com
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unless otherwise stated.JIA is currently described by the International League of
Associations for Rheumatism (ILAR) classification system
as a disease comprising seven categories, based on clinical
characteristics, heredity and laboratory results [2]. While
IgM rheumatoid factor (RF) is a determinant of the
polyarticular categories, occurrence of IgA RF and anti-
citrullinated peptide antibodies (ACPA), for which the
most common clinical test is anti-cyclic citrullinated pep-
tide (anti-CCP), are not included in the ILAR classification.
In population-based studies on JIA, IgM RF has an oc-
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articular disease, higher age at onset and a higher risk of
joint damage. IgA RF has been studied far less, but is
also discussed as a risk factor for joint space narrowing
or joint erosions [5].
In RA, anti-CCP can be detected several years before
disease onset [6], has a high disease specificity, and is
now included in the 2010 classification criteria for RA
[7]. The prognostic role of anti-CCP in JIA resembles
that of IgM RF. Anti-CCP has low prevalence (2–15%)
and is present in particular in the RF-positive, polyarticu-
lar JIA category [8-10]. The majority of JIA study cohorts
on ACPA are small. Results depend on the methods used
for analysis, cut-off values for autoantibody analyses and
patient selection.
Autoantibodies against collagen type II (anti-CII) have
been studied in adult RA (11–14). CII is the predomin-
ant hyaline cartilage collagen. Patients with anti-CII
make up a distinct RA phenotype, found in a minority
of adult RA patients, associated with acute inflammation
at disease onset [11] and early radiographic destruction
[12]. Anti-CII has been shown to induce the proinflam-
matory cytokines TNFα, IL-1β and IL-8, when incorpo-
rated in immune complexes in vitro [13]. These findings
are in concordance with earlier reports showing that
high anti-CII levels are associated with higher levels of
ESR, CRP, TNFα and IL-6 compared with what is found
in anti-CII negative RA patients [14]. Anti-CII positive
RA patients also experience less diagnostic delay [11],
probably because of the high inflammatory activity. In
contrast to ACPA and RF, anti-CII does not precede the
development of RA by a long time period [6,15]. Earlier
studies have shown that levels of anti-CII decrease shortly
after RA diagnosis [11,16], and therefore studies of anti-
CII should preferably be performed on sera obtained early
at or soon after disease onset. The anti-CII phenotype in
adult RA thus seems to be a temporary finding around the
time of symptom onset and diagnosis [12]. Data regarding
anti-CII in JIA are scarce [17].
Our aim was to study whether early occurrence of anti-
CII, IgM RF, IgA RF and/or anti-CCP, in a well-defined co-
hort of children with JIA, could be related to outcome
data and joint damage after eight years of disease.
Methods
Patients
The Nordic JIA database consists of 440 patients followed
prospectively for a median of 97 months (IQR 95–105) in
a population-based approach and classified according to
the ILAR criteria after eight years of disease [2]. From this
database, 192 patients with (available) sera taken within
12 months after disease onset were included. Due to these
inclusion criteria, this sub-study cannot be considered
population-based. Data of CRP results ≤ 10 months afterdisease onset were included if available. At the eight-year
follow-up visit, remission according to the preliminary cri-
teria of Wallace et al. [18], and joint damage according to
Juvenile Arthritis Damage Index for Articular damage
(JADI-A) (scale 0–72 where 0 means no damage) [19],
were assessed by a paediatric rheumatologist in 147 of the
patients. We found no statistical difference between the
original 440 patients and the 147 patients studied as
regards gender, age of onset or proportion of oligoarticular
persistent patients.
Analyses of autoantibodies
For autoantibody analyses we used sera stored at −70°C,
collected within a median of four months (IQR 2–7)
after disease onset. IgM RF, IgA RF and anti-CCP were
analysed using the Phadia ImmunoCAP enzyme immuno-
assay, allowing isotype-specific analysis of IgM and IgA
RF. For anti-CCP, the cut-off value at Uppsala University
Hospital of > 7 U/ml was used, which is a commonly used
cut-off value in many laboratories. The reference ranges
for IgM (>5 U/ml) and IgA RF (>9 U/ml) were established
with 100 healthy adult donors, using the reference range
criteria (>95% diagnostic specificity) determined based on
the 1987 ACR RA classification criteria [20]. Analysis of
anti-CII IgG was performed with an in-house enzyme-
linked immunosorbent assay (ELISA), using the cut-off
(>29 U/ml) set at 95% specificity among 100 healthy adult
blood donors as described earlier [11,12].
Statistical methods
Conventional descriptive statistics were used; median
and interquartile ranges (IQR) were given. For independ-
ent samples the Mann–Whitney U test was used and for
analysis of proportions Fisher’s exact test was employed,
due to the low number of antibody-positive patients. Cor-
relations were assessed using Spearman’s rank correlation
coefficients (ρ). P-values of less than 0.05 were considered
statistically significant for two-tailed tests. Analyses were
carried out using the Statistical Package for Social Sci-
ences (SPSS), version 20 (IBM SPSS Statistics) and JMP
(SAS Institute).
Ethical issues
The Research Ethical Committees in each country gave
their approval in accordance with national practice and
legislation. In Sweden the study was approved by the Re-
gional Ethical Review Board at Uppsala. Written informed
consent was obtained from patients > 16 years and from
parents for children aged < 16 years.
Results
All ILAR categories were represented in the patient cohort,
of which 69.3% were female (Table 1). The oligoarticular
persistent group was the largest (46.9% of the total cohort).
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serum samples, IgM RF in 3.6%, IgA RF in 3.1%, anti-CCP
in 2.6%.
Occurrence of RF and anti-CCP did overlap to some
extent, but rarely with anti-CII (Table 2). The polyarticu-
lar and oligoarticular extended categories were overrep-
resented in patients with two or more of the four
autoantibodies present. In two patients (patients 8 and 9
in Table 2), the anti-CCP value was more than ten times
higher than in other anti-CCP positive patients.
The median age of onset was significantly higher in pa-
tients with IgM as compared with patients without these
antibodies, while patients with anti-CII had onset ages
comparable to those of the total JIA cohort (Table 3). JADI-
A for joint damage was assessed in 147 patients and found
to be > 0 in 18 patients. All four autoantibodies were signifi-
cantly associated with joint damage according to JADI-A
after eight years, with the strongest associations found for
IgA RF and anti-CCP (Table 3). The occurrence of any of
the investigated autoantibodies was also strongly associated
with elevated JADI-A (p = 0.0004, Table 3). There was,
however, no significant association between the presence of
these autoantibodies and cumulative number of joints af-
fected, ongoing disease activity, or remission at eight years.
When patient antibodies were correlated to the JADI-
A scores, we found a highly significant association to the
number of antibodies detected (p = 0.0001). The correl-
ation coefficients were, however, low for the commonly
tested antibodies (anti-CCP, IgM RF and IgA RF) (Spear-
man’s ρ = 0.30) and did not increase when anti-CII were
included (Spearman’s ρ = 0.31).
Information on CRP levels taken ≤ 10 months after
disease onset were available for 134/192 patients. CRP
taken early in the disease course were significantly
higher (more than four times higher) in anti-CII positive
patients than in anti-CII negative patients (median 30.0
vs. 8.7 mg/l; p = 0.0001). No such association was found
for any of the other antibodies studied (Figure 1).Table 1 Prevalence of autoantibodies during the first year of
idiopathic arthritis database classified after a median of eigh
ILAR* category Total cohort
n (%)
Girls/boys
n (% girls)
IgM RF-
n (%)
Systemic 9 (4.7%) 5/4 (55%) 1
Oligoarticular persistent 90 (46.9%) 60/30 (66.6%) 2
Oligoarticular extended 8 (4.2%) 8/0 (100%) 1
Polyarticular RF-negative 40 (20.8%) 30/10 (75.0%) -
Polyarticular RF-positive 1 1/0 1
Juvenile psoriatic arthritis 1 0/1 -
Enthesitis-related arthritis 15 (7.8%) 5/10 (33.3%) -
Undifferentiated arthritis 28 (14.6%) 24/4 (85.7%) 2
Total 192 133/59 (69.3%) 7 (3.6%)
*International League of Associations for Rheumatology classification criteria [2].Discussion
As far as we know, this is the first study investigating
the long-term prognostic impact of antibodies against
native CII in JIA. Occurrence of anti-CII rarely over-
lapped with anti-CCP, IgA RF and IgM RF, and was seen
in a younger age group at disease onset than the other
three conventional autoantibodies. All four autoanti-
bodies were associated with clinical assessment of joint
damage according to JADI-A after a median of eight
years of disease.
A strength of this study is that it includes all JIA cat-
egories, and that analysed serum samples were collected
early in the disease course. This is in contrast to other
studies on autoantibodies in JIA, where samples have
been collected at different times after disease onset. This
early sampling was also a prerequisite for the analysis of
anti-CII, as previous studies have shown that anti-CII
levels peak around the time of RA diagnosis [11].
Limitations of our study were the small number of
autoantibody-positive patients, and that no data on
radiological damage was available for assessment of joint
damage. The JADI-A index used in this study is vali-
dated and considered useful as an instrument for the
clinical assessment of long-term articular damage in pa-
tients with JIA, but the index mainly collects severe ar-
ticular changes [19]. Radiographical methods do not
fully reflect the spectrum of articular damage in children
since contractures and restricted range of movement can
also depend on extraarticular damage. An advantage of
using the JADI-A is that it includes restricted range of
movement and joint damage not necessarily detected by
radiography. A limitation is that autoantibodies were
analysed at only one time point, which might include
false positive serum samples. In order to be classified as
RF-positive JIA, two positive tests at least three months
apart are required (2). Adult and not age-matched cut-off
values were used for the conventionally used autoanti-
bodies (IgM RF, IgA RF and anti-CCP) [17]. We thereforedisease in 192 patients from the Nordic juvenile
t years of disease according to the ILAR* criteria
positive IgA RF-positive
n (%)
IgG anti-CCP
positive n (%)
IgG anti-collagen
II positive n (%)
0 1 0
- - 2
1 1 -
1 1 2
1 - -
- - -
2 1 1
1 1 1
6 (3.1%) 5 (2.6%) 6 (3.1%)
Table 2 Patterns of autoantibodies collected in 17 of 192 patients from the Nordic juvenile idiopathic arthritis
database
Patient
No
Age at time
of onset
IgM RF
Cut-off
IgA RF
Cut-off
IgG Anti-CCP
Cut-off
IgG Anti-Collagen II
Cut-off
Articular
damage¤
JIA category# Cumulative number
of joints affected
during the first eight
years of disease
Years > 5 U/ml > 9 U/ml > 7 U/ml > 29 U/ml
1 4.4 5.7 - - - Missing Systemic 4
2 12.8 6.0 - - - - Oligoarticular persistent 2
3 13.5 23.0 - - - - Undifferentiated* 1
4 9.4 5.5 - - - - Oligoarticular persistent 2
5 9.3 - 13.0 - - - Enthesitis-related arthritis 4
6 1.5 - 14.0 - - 1 Oligoarticular extended 18
7 13.2 64.0 17.0 - - 1 Polyarticular RF-positive 13
8 13.3 132.0 67.0 ≥ 340 - 1 Undifferentiated** 18
9 10.9 17.0 - ≥ 340 - 1 Oligoarticular extended 24
10 1.1 - - 9.8 - - Systemic 6
11 11.8 - 23.0 15.0 - - Enthesitis-related arthritis 2
12 11.0 - 11.0 12.0 94.3 1 Polyarticular RF-negative 19
13 11.7 - - - 35.9 1 Polyarticular RF-negative 34
14 4.0 - - - 46.6 - Enthesitis-related arthritis 13
15 4.8 - - - 30.4 - Oligoarticular extended 9
16 4.3 - - - 72.9 - Undifferentiated*** 2
17 8.1 - - - 230.8 Missing Oligoarticular persistent 1
¤Articular damage at eight-year follow-up according to JADI-A (score 0–72) [19].
#ILAR Edmonton criteria after eight years of disease [2].
*Oligoarticular persistent joint pattern and presence of IgM rheumatoid factor on two occasions more than three months apart.
**Polyarticular pattern from onset and psoriasis in first degree relative.
***Oligoarticular persistent joint pattern and psoriasis in first degree relative.
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cut-off values were locally validated using 100 healthy in-
dividuals, and specificities adjusted to 95–97% according
to the currently used definition of RF specificity as defined
in the previous ACR classification criteria for RA [20], not
changed in the more recent EULAR/ACR criteria [7].
Occurrence of autoantibodies was rare in our study,
much like in the majority of previous studies on JIA
[9,21-23]. As in adult RA, occurrence of IgM RF in JIA
has been shown to correlate with joint damage or joint
space narrowing [5,17,22,24-26]. Our results were in line
with these studies, as we found a significant association
with joint damage in the IgM RF-positive patients.
Children with oligoarticular JIA have occasionally been
found to be IgM RF-positive. Our results gave no indica-
tions of a more severe disease in these children. The
three IgM RF-positive patients in our study with high
age at onset and oligoarticular joint pattern throughout
the disease course did not have any joint damage after
eight years of disease. These patients also lacked any of
the other autoantibodies investigated in the study. This
might indicate that positive IgM RF in an oligoarticular
disease is of little significance if the patient lacks anti-
CCP or IgA RF.Several studies on JIA point to a high co-occurrence of
IgM RF and anti-CCP [8,26,27], but they may also occur in-
dependently [28]. JIA patients with IgM RF and/or anti-
CCP generally present at a higher age than patients without
these antibodies [29]. In line with these results, the IgM
RF-positive children with articular damage in our study had
a high age at onset, a polyarticular or oligoarticular ex-
tended disease pattern, and were IgA RF or anti-CCP posi-
tive as well. The anti-CCP levels in these children were also
very high. It has been suggested that JIA patients positive
for both IgM RF and anti-CCP present a more severe dis-
ease phenotype than those with only one autoantibody [30].
In line with this, we can report that co-occurrence of IgA
RF and possibly of anti-CII is associated with severe joint
damage after eight years of disease in JIA.
We found an association between anti-CCP and joint
damage. This is supported by several earlier studies show-
ing an increased risk for radiological bone damage in pa-
tients with anti-CCP in JIA [17,22,26,28]. Four of five anti-
CCP positive patients in our study were more than
10 years old at onset; the fifth was one year old and had
systemic JIA. However, others have presented a separate
group of children with only anti-CCP and young age of
onset [21].
Table 3 Analyses of autoantibodies in 147 patients from the Nordic JIA database followed for eight years in
association with age at disease onset, number of cumulative joints, remission and articular damage
Total Age at onset
(n = 147)
Cumulative joints
during the first eight
years of disease (n = 147)
Remission after
8 years (n = 147)
Articular damage***
at eight year follow
up (n = 147)
n (%) Median (IQR) p* Median (IQR) p* Number of patients
without remission/total
number (%)
p** Number of patients
with damage/total
number (%)
p**
Total cohort 147 5.4 (2.8-9.9) 8 (3–15) 99/147 (67%) 18/147 (12)
IgM RF positive 6 (4.1%) 10.5 (13.0-13.4) 0.002 8 (2–20) 0.79 3/6 (50%) 0.39 3/6 (50) 0.0068
IgA RF positive 6 (4.1%) 11.4 (7.6-13.2) 0.07 16 (4–18) 0.57 1/6 (17%) 0.66 4/6 (67) 0.0001
Anti-CCP positive 5 (3.4%) 11.0 (6.0-12.6) 0.15 18 (4–22) 0.89 1/5 (20%) 1.00 3/5 (60) 0.0007
Anti-collagen II
positive
5 (3.4%) 4.8 (4.2-11.4) 0.54 13 (6–26) 0.29 2/5 (40%) 0.66 2/5 (40) 0.0274
Any conventional#
antibody
5/11 0.0004
Any antibody¤ 6/15 0.0004
*Mann–Whitney U test, as compared with patients without the corresponding autoantibody.
**Fisher’s Exact Test, as compared with patients without the corresponding autoantibody.
***Articular damage at eight-year follow-up according to JADI-A (score 0–72).
#Positive for one or more antibodies: IgM RF, IgA RF and/or anti-CCP.
¤Positive for one or more antibodies: IgM RF, IgA RF, anti-CCP and/or anti-collagen II.
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more than ten times higher than the rest of the group.
This is in concordance with adult RA, where anti-CCP
positive individuals generally have levels clearly above
the cut-off [31]. Others have found anti-CCP levels to be
higher in IgM RF-positive patients with JIA compared
with IgM RF-negative patients [21]. A very high level of
anti-CCP at diagnosis should most likely be considered
in prognostic evaluation and risk assessment for articu-
lar damage in children with JIA [22].
Studies on IgA RF and joint damage in JIA are limited.
In our study, we found the strongest association betweenan
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Figure 1 Association between the occurrence of four autoantibodies
blood samples were obtained≤ 10 months after onset of disease. P-v
and without the corresponding autoantibodies investigated with the Mann
levels≤ 10 mg/L were set to 3 g/L.IgA RF and joint damage after eight years of disease.
This is supported by two previous studies presenting an
increased risk for joint space narrowing or erosions in
JIA patients with IgA RF [5,17]. In adults, a number of
studies have indicated IgA RF as a stronger predictor for
poor radiological prognosis than IgM RF [32,33]. High
levels of IgA RF have also been shown to predict poor
response to TNF inhibition in RA [34].
Only six patients were positive for anti-CII antibodies
in our study, but the association with joint damage was
statistically significant. Interestingly, this group of chil-
dren had a median age of onset of 6.4 years, very closeIg
A 
RF
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-
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p=0.21 p=0.0001
and early CRP levels in 134 (of 192) patients with JIA where
alues denote differences in median CRP levels between patients with
-Whitney’s U test. Horizontal lines indicate median levels. All CRP
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anti-CCP positive patients, who had a higher age of on-
set (Table 3). The young age at onset and the low fre-
quency of overlap with the other autoantibodies indicate
that the anti-CII JIA phenotype might differ from the
RF/anti-CCP positive phenotypes. In RA, elevated levels
of anti-CII at diagnosis represent an acute onset pheno-
type with high CRP [11,12], whereas anti-CCP and RF-
positive individuals do not differ from autoantibody-
negative individuals at baseline, but have a significantly
poorer prognosis [35]. Anti-CII and anti-CCP do not only
represent clinically opposite phenotypes in adult RA, but
their occurrence is statistically inversely related [11]. Our
result of an increased risk of joint damage after eight years
of disease in anti-CII positive JIA patient differs from find-
ings in adult RA, where anti-CII positive individuals have
acute inflammation [11] and more radiological destruc-
tions [12] at disease onset, but not later, when levels of
anti-CII decline. Although the number of anti-CII positive
JIA patients is low, our study indicates that CRP levels are
high during early disease in anti-CII positive children with
JIA, as they are in adults with RA. In the present study,
the median early CRP level was more than four times
higher among anti-CII positive than among anti-CII nega-
tive JIA patients. In a previous study, using exactly the
same anti-CII ELISA as employed in this study, the mean
CRP levels were increased 2.5-fold at the time of diagnosis
in anti-CII positive adult RA patients (53 vs 21 mg/l, p <
0.0001) [11]. We hypothesize that these elevated CRP
levels in anti-CII positive JIA patients may be due to pro-
duction of proinflammatory cytokines by monocytes stim-
ulated with anti-CII containing immune complexes, as
was described in adult RA [11,13].
We do not know how anti-CII develops over time in
JIA patients. In adult RA, levels are not increased before
diagnosis [15] and quickly decrease after [11,16]. If anti-
CII levels are only transiently elevated at the time of
diagnosis in JIA, early serum sampling as employed in
our study should be recommended.
We are only aware of one recent study on anti-CII in
JIA [17]. In that study, encompassing 95 patients with
disease duration varying between 0.4 and 9.5 (median
2.0) years and thus with later serum sampling than in
our study, 17.9% had antibodies against native CII [11].
Anti-CII were not associated with more joint erosions at
the time of serum sampling, but the study did not in-
clude any clinical or radiological follow-up data to eva-
luate the prognostic impact of anti-CII [17].
Our findings suggest that occurrence of anti-CII, anti-
CCP, IgM RF or IgA RF analysed at an early stage of dis-
ease may predict later joint damage. We suggest analysis
of IgM and IgA RF as well as anti-CCP in all newly diag-
nosed children with JIA. We also suggest special attention
to patients with more than one of these autoantibodiespresent. The role for anti-CII in JIA should be more ex-
tensively studied.
Conclusions
Occurrence of anti-CII, anti-CCP, IgM RF or IgA RF
analysed at an early stage of disease may predict later
joint damage. Patients with more than one of these auto-
antibodies present merit special attention. Anti-CII in
JIA seems to characterize a different subset of JIA pa-
tients than the other antibodies, associated with in-
creased CRP levels early after disease onset, and with
clinical joint damage after eight years.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors were involved in drafting the article or revising it critically for
important intellectual content. All authors also approved the final version to
be published and agreed to be accountable for all aspects of the work.
Dr. LB had full access to all data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis. LB, JR study
conception and design. LB, EN, AF, KA, TH, SN, MR, MZ, JR acquisition of
data. LB, JR analysis and interpretation of data.
Acknowledgements
On behalf of Nordic Study Group of Pediatric Rheumatology (NoSPeR)
We thank the other members of the Nordic Study group of Pediatric
Rheumatology (NoSPeR): Gudmund Marhaug in Trondheim, Freddy Karup
Pedersen in Copenhagen, Suvi Peltoniemi in Helsinki and Boel Anderson-
Gäre in Jönköping, Sweden. Lastly, we thank participating physicians who
contributed by collecting data: Astri Lang and Anne Elisabeth Ross in
Tromsø, Kjell Berntzen and Nina Moe in Trondheim, Mikael Damgaard, Maria
Ekelund and Nils Olof Jonsson, Jönköping, Anders Berner and Hans Ekström,
Karlstad, Eric Ronge, Skövde, Agne Lind and Lars Hammarén, Borås, Johan
Robinsson, Trollhättan and Anna-Lena Nilsson, Östersund.
This work was supported by grants from the Department of Women’s and
Children’s Health, Uppsala University Hospital, Uppsala, the Gillbergska
foundation, Uppsala, the Swedish Research Council, the Swedish
Rheumatism Association, the Queen Silvia Children’s Hospital, Göteborg, and
the Dalarna Clinical Research Institute, Falun, Sweden.
Author details
1Department of Women’s and Children’s Health, Uppsala University, Uppsala,
Sweden. 2Department of Pediatrics, University Hospital of North Norway,
Tromsø, Norway. 3Institute of Clinical Medicine, University of Tromsø, Tromsø,
Norway. 4Department of Pediatrics, University of Gothenburg, Gothenburg,
Sweden. 5Department of Pediatrics, Children’s Hospital, Helsinki University
Hospital, Helsinki, Finland. 6Århus University Hospital, Skejby, Århus, Denmark.
7University Clinic of Pediatrics II, Rigshospitalet, Copenhagen, Denmark.
8Department of Laboratory Medicine, Children’s and Women’s Health,
Norwegian University of Science and Technology, Trondheim, Norway.
9Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway.
10Department of Immunology, Genetics and Pathology, Uppsala University,
Uppsala, Sweden.
Received: 18 February 2014 Accepted: 6 June 2014
Published: 11 June 2014
References
1. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen
S, Straume B, Rygg M: Ongoing disease activity and changing categories
in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis
Rheum 2011, 63(9):2809–2818.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X,
Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Patricia
W, and International League of Associations for Rheumatology: Inter-
national League of Associations for Rheumatology classification of
Berntson et al. Pediatric Rheumatology 2014, 12:22 Page 7 of 7
http://www.ped-rheum.com/content/12/1/22juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol
2004, 31(2):390–392.
3. Modesto C, Anton J, Rodriguez B, Bou R, Arnal C, Ros J, Tena X, Rodrigo C,
Rotes I, Hermosilla E, Barceló P: Incidence and prevalence of juvenile
idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol 2010, 39(6):472–479.
4. Berntson L, Andersson Gare B, Fasth A, Herlin T, Kristinsson J, Lahdenne P,
Marhaug G, Nielsen S, Pelkonen P, Rygg M: Incidence of juvenile
idiopathic arthritis in the Nordic countries. a population based study
with special reference to the validity of the ILAR and EULAR criteria.
J Rheumatol 2003, 30(10):2275–2282.
5. Gilliam BE, Chauhan AK, Low JM, Moore TL: Measurement of biomarkers in
juvenile idiopathic arthritis patients and their significant association with
disease severity: a comparative study. Clin Exp Rheumatol 2008, 26(3):492–497.
6. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund
H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated
peptide and IgA rheumatoid factor predict the development of
rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741–2749.
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd,
Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader
KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga
TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland
LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et
al: 2010 Rheumatoid arthritis classification criteria: an American College
of Rheumatology/European League Against Rheumatism collaborative
initiative. Arthritis Rheum 2010, 62(9):2569–2581.
8. van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH,
de Jong B, Dijkmans B, van Venrooij WJ: Anti-cyclic citrullinated peptide
(anti-CCP) antibodies in children with juvenile idiopathic arthritis. J
Rheumatol 2003, 30(4):825–828.
9. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V,
Cecchini G, Borghi MO, Meroni PL: Prevalence and clinical significance of
anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.
Ann Rheum Dis 2002, 61(7):608–611.
10. Hromadnikova I, Stechova K, Pavla V, Hridelova D, Houbova B, Voslarova S,
Nekvasilova H, Vavrinec J: Anti-cyclic citrullinated peptide antibodies in
patients with juvenile idiopathic arthritis. Autoimmunity 2002, 35(6):397–401.
11. Mullazehi M, Mathsson L, Lampa J, Rönnelid J: High anti-collagen type-II
antibody levels and induction of proinflammatory cytokines by anti-
collagen antibody-containing immune complexes in vitro characterise a
distinct rheumatoid arthritis phenotype associated with acute inflammation
at the time of disease onset. Ann Rheum Dis 2007, 66(4):537–541.
12. Mullazehi M, Wick MC, Klareskog L, van Vollenhoven R, Rönnelid J:
Anti-type II collagen antibodies are associated with early radiographic
destruction in rheumatoid arthritis. Arthritis Res Ther 2012, 14(3):R100.
13. Mullazehi M, Mathsson L, Lampa J, Rönnelid J: Surface-bound anti-type II
collagen-containing immune complexes induce production of tumor
necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral
blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic
mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis
Rheum 2006, 54(6):1759–1771.
14. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK,
Hong YS, Lee SH, Park SH, Cho CS, Kim HY: IgG antibodies to type II
collagen reflect inflammatory activity in patients with rheumatoid
arthritis. J Rheumatol 2000, 27(3):575–581.
15. Mottonen T, Hannonen P, Oka M, Rautiainen J, Jokinen I, Arvilommi H,
Palosuo T, Aho K: Antibodies against native type II collagen do not
precede the clinical onset of rheumatoid arthritis. Arthritis Rheum 1988,
31(6):776–779.
16. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P: Antibodies to type II
collagen in early rheumatoid arthritis. correlation with disease
progression. Arthritis Rheum 1996, 39(10):1720–1727.
17. Gilliam BE, Chauhan AK, Moore TL: Evaluation of anti-citrullinated type II
collagen and anti-citrullinated vimentin antibodies in patients with
juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2013, 11(1):31.
18. Wallace CA, Ruperto N, Giannini E: Preliminary criteria for clinical
remission for select categories of juvenile idiopathic arthritis. J Rheumatol
2004, 31(11):2290–2294.
19. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N,
Rossi F, Bartoli M, Martini A, Ravelli A: Development and validation of a
clinical index for assessment of long-term damage in juvenile idiopathic
arthritis. Arthritis Rheum 2005, 52(7):2092–2102.20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism
Association 1987 revised criteria for the classification of rheumatoid
arthritis. Arthritis Rheum 1988, 31(3):315–324.
21. Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, McNally B, Hill
HR, Bohnsack J, Prahalad S: Profiling anti-cyclic citrullinated peptide anti-
bodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol
Online J 2012, 10(1):29.
22. Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, Saribas
S, Arisoy N, Kocazeybek B: Diagnostic accuracy of anti-cyclic citrullinated
peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004,
63(12):1687–1689.
23. Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N: Antibodies
to mutated citrullinated vimentin and antibodies to cyclic citrullinated
peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 2009,
47(12):1525–1530.
24. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ:
Rheumatoid factor is the major predictor of increasing severity of
radiographic erosions in rheumatoid arthritis: results from the Norfolk
Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002,
46(4):906–912.
25. Bas S, Genevay S, Meyer O, Gabay C: Anti-cyclic citrullinated peptide
antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis
of rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(5):677–680.
26. Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, Emad Y: Anti-
cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic
arthritis (JIA): correlations with disease activity and severity of joint dam-
age (a multicenter trial). Joint Bone Spine 2013, 80(1):38–43.
27. Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL: Evidence of
fibrinogen as a target of citrullination in IgM rheumatoid factor-positive
polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2011,
9:8.
28. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, Kim DL, Jones BM:
Anti-cyclic citrullinated peptide: diagnostic and prognostic values in
juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese
population. Scand J Rheumatol 2005, 34(5):359–366.
29. Dewint P, Hoffman IE, Rogge S, Joos R, Union A, Dehoorne J, Delanghe J,
Veys EM, De Keyser F, Elewaut D: Effect of age on prevalence of
anticitrullinated protein/peptide antibodies in polyarticular juvenile
idiopathic arthritis. Rheumatology (Oxford) 2006, 45(2):204–208.
30. Syed RH, Gilliam BE, Moore TL: Rheumatoid factors and anticyclic
citrullinated peptide antibodies in pediatric rheumatology. Curr
Rheumatol Rep 2008, 10(2):156–163.
31. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van
Vollenhoven RF: Longitudinal analysis of citrullinated protein/peptide
antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis:
anti-CP status predicts worse disease activity and greater radiological
progression. Ann Rheum Dis 2005, 64(12):1744–1749.
32. Jonsson T, Arinbjarnarson S, Thorsteinsson J, Steinsson K, Geirsson AJ,
Jonsson H, Valdimarsson H: Raised IgA rheumatoid factor (RF) but not IgM
RF or IgG RF is associated with extra-articular manifestations in rheuma-
toid arthritis. Scand J Rheumatol 1995, 24(6):372–375.
33. Jorgensen C, Legouffe MC, Bologna C, Brochier J, Sany J: IgA isotype
rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp
Rheumatol 1996, 14(3):301–304.
34. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C,
Montecucco C: High IgA rheumatoid factor levels are associated with
poor clinical response to tumour necrosis factor alpha inhibitors in
rheumatoid arthritis. Ann Rheum Dis 2007, 66(3):302–307.
35. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog
L, Rönnelid J: Antibodies against citrullinated vimentin in rheumatoid
arthritis: higher sensitivity and extended prognostic value concerning
future radiographic progression as compared with antibodies against
cyclic citrullinated peptides. Arthritis Rheum 2008, 58(1):36–45.
doi:10.1186/1546-0096-12-22
Cite this article as: Berntson et al.: Anti-type II collagen antibodies,
anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed
eight years after onset of juvenile idiopathic arthritis (JIA). Pediatric
Rheumatology 2014 12:22.
